Eris Lifesciences acquires trademark Zomelis from Novartis AG for India market

Eris Lifesciences acquires trademark Zomelis from Novartis AG for India market

Zomelis is used in the treatment of type 2 diabetes and comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors.

This is the first innovator pharmaceutical product trademark acquisition by Eris.

News Links

Copyright © 2021 Eris Lifesciences Limited. All Rights Reserved.